2 min read

Cleerly Announces Key Leadership Promotions: Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer

Picture of Cleerly Cleerly : July 1, 2025

AI-enabled CCTA approach heart attack prevention

Cleerly Announces Key Leadership Promotions: Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer

Strategic promotions strengthen Cleerly's executive team as company accelerates growth

July 1, 2025 (DENVER, CO) – Cleerly, the leader in cardiovascular imaging, today announced the promotions of two key executives to expanded leadership roles. Dr. Udo Hoffmann, MD, MPH, has been promoted to Chief Medical, Scientific and AI Officer, while Amit Relia has been named Chief Regulatory Officer. These strategic promotions position Cleerly for accelerated growth and expansion while reinforcing the company's commitment to scientific rigor and advancement of cardiovascular care through technological excellence.

Dr. Udo Hoffmann Promoted to Chief Medical, Scientific and AI Officer

Dr. Hoffmann, who joined Cleerly in 2022 as Chief Scientific Officer, will now oversee Scientific Affairs, Medical Affairs, Core Laboratory, Data Science/AI, and Regulatory and Quality departments in his expanded role.

Prior to Cleerly, Dr. Hoffmann served as Professor of Radiology at Harvard Medical School, Chief of the Division of Cardiovascular Imaging at the Department of Radiology at Massachusetts General Hospital (MGH), and was the Founding Director of the MGH Cardiovascular Imaging Research Center. He led landmark NIH clinical trials including ROMICAT I and II, PROMISE, and REPRIEVE; his work has resulted in over 600 peer-reviewed publications in journals such as the New England Journal of Medicine and The Lancet.

Amit Relia Named Chief Regulatory Officer

Amit Relia, who joined Cleerly as VP of Regulatory Affairs and Quality Assurance in 2024, has been promoted to Chief Regulatory Officer to shape regulatory strategy as Cleerly expands.

Prior to Cleerly, Relia led regulatory initiatives at iRhythm Technologies for AI/ML cardiac devices, guided global regulatory strategy for ECG-based software at Apple Health launching in 47 countries, and influenced landmark clearances for surgical robotic devices at Intuitive. Relia has consistently ensured robust regulatory compliance frameworks at the companies he served, laying the groundwork for growth and technological breakthroughs.

"Both Udo and Amit have been instrumental to our success and will drive our next phase of growth," said Dr. Jim Min, Founder and CEO of Cleerly. "Udo has had a storied career leading cardiovascular imaging research and is a proven leader who has served as a core member of Cleerly's management team, ensuring our company growth is highly disciplined, thoughtful, and technically innovative. Amit has built a solid regulatory strategy that will help shape foundational excellence across all areas of regulatory compliance."

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.